Welcome to our dedicated page for Cingulate Warrants news (Ticker: CINGW), a resource for investors and traders seeking the latest updates and insights on Cingulate Warrants stock.
Cingulate Inc is a clinical-stage biopharmaceutical company utilizing its proprietary precision timed-release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic areas to use PTR technology to develop future product candidates.
Latest News: "Today we are pleased to welcome Jennifer Callahan to the C-Suite, and thank Lou Van Horn for his commitment, hard work, and guidance as Cingulate's CFO through many important milestones," stated Cingulate Chairman and CEO Shane J. Schaffer. "Jenny has worked closely with Lou and is a valued and trusted member of our management. Her leadership and expertise were instrumental during Cingulate's IPO, and we look forward to a seamless transition as we begin this new chapter." Callahan, who brings decades of accounting and financial experience to Cingulate's C-Suite, said she's excited to lead the finance team into the future and hopes to help the company raise capital in an efficient and timely manner.
"It's been a pleasure advancing the Cingulate mission for the past seven years, and I am honored to be named its next Chief Financial Officer," Callahan said. "As we move forward, capital remains imperative to the long-term success of Cingulate, and we will seek to strengthen our balance sheet through both traditional and non-dilutive transactions."
About Cingulate Inc.
Cingulate Inc. (NASDAQ: CING), is a biopharmaceutical company utilizing its proprietary PTR drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. With an initial focus on the treatment of ADHD, Cingulate is identifying and evaluating additional therapeutic areas where PTR technology may be employed to develop future product candidates, including to treat anxiety disorders. Cingulate is headquartered in Kansas City.
Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements include all statements, other than statements of historical fact, regarding our current views and assumptions with respect to future events regarding our business, including statements with respect to our plans, assumptions, expectations, beliefs and objectives with respect to product development, clinical studies, clinical and regulatory timelines, market opportunity, competitive position, business strategies, potential growth opportunities and other statements that are predictive in nature. These statements are generally identified by the use of such words as "may," "could," "should," "would," "believe," "anticipate," "forecast," "estimate," "expect," "intend," "plan," "continue," "outlook," "will," "potential" and similar statements of a future or forward-looking nature. Readers are cautioned that any forward-looking information provided by us or on our behalf is not a guarantee of future performance. Actual results may differ materially from those contained in these forward-looking statements as a result of various factors disclosed in our filings with the Securities and Exchange Commission (SEC), including the "Risk Factors" section of our Annual Report on Form 10-K filed with the SEC on March 10, 2023. All forward-looking statements speak only as of the date on which they are made, and we undertake no duty to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except to the extent required by law.
Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company, announced that Chairman & CEO Shane J. Schaffer will present at the LD Micro Main Event XV investor conference on October 26, 2022, at 10:00 a.m. PT. The event will take place at the Luxe Sunset Boulevard Hotel in Los Angeles, with live streaming available at this link. The company, utilizing its Precision Timed Release™ (PTR™) technology, focuses on developing next-generation pharmaceutical products for neurological disorders and other therapeutic areas.
Cingulate Inc. (NASDAQ: CING) announced findings from a formulation study for CTx-2103, a once-daily buspirone treatment for anxiety disorders, presented at the 2022 Psych Congress. The study demonstrated the ability of CTx-2103 to deliver a triple-release formulation, enhancing patient compliance and treatment outcomes. The CEO emphasized the importance of formulation development in achieving effective medications. CTx-2103 aims to provide benefits over existing treatments by eliminating the need for multiple daily doses.
Cingulate Inc. (NASDAQ: CING) announced that Chairman and CEO Shane J. Schaffer will speak at the Benzinga All Access event on August 19, 2022, at 9 a.m. CST. The discussion will focus on unmet needs in Attention Deficit/Hyperactivity Disorder (ADHD) and the expansion of Cingulate’s Precision Timed Release™ (PTR™) platform into anxiety treatment. The event can be viewed live on Benzinga’s YouTube channel and on Cingulate’s investor website.
Cingulate is dedicated to improving treatment outcomes for patients through innovative drug delivery technology.
Cingulate Inc. (NASDAQ: CING) announced its Q2 financial results, highlighting a $5 million non-dilutive debt financing and the appointment of Scott Applebaum to its Board of Directors. As of June 30, 2022, Cingulate's cash and equivalents stood at $8.2 million. R&D expenses rose to $2.2 million, while G&A expenses increased to $1.9 million, leading to a net loss of $4 million for the quarter. The company plans to continue development of its ADHD treatment, CTx-1301, with a Phase 3 study expected to commence soon. Positive NDA filing anticipated by late 2023 requires additional capital of $16.5 million.
Cingulate Inc. (NASDAQ: CING), a clinical-stage biopharmaceutical company, announced that its CFO, Lou Van Horn, was honored as a 2022 CFO of the Year by the Kansas City Business Journal. This is the second time Lou has received this accolade, recognizing his financial leadership and expertise. The award ceremony took place on July 22, 2022. Lou, who played a crucial role in Cingulate's IPO in 2021, expressed gratitude for the recognition and highlighted the positive economic outlook for the Kansas City region.
Cingulate Inc. has announced the completion of the formulation study for CTx-2103, a new once-daily treatment for anxiety-related disorders using its proprietary Precision Timed Release™ (PTR™) drug delivery technology. This study, conducted in the UK, aims to improve adherence by reducing the dosing frequency of the active ingredient, buspirone. Results are anticipated in August 2022. CTx-2103 is designed to offer significant advantages over existing medications while addressing a substantial market need, as anxiety disorders affect approximately 31% of U.S. adults at some point in their lives.
Cingulate Inc. (NASDAQ: CING), a clinical-stage biopharmaceutical company, will present a company overview at the Diamond Equity Research 2022 Virtual Emerging Growth Invitational on June 23, 2022, at 1:40 PM EST. Chairman and CEO, Shane J. Schaffer, PharmD, will lead the presentation and follow up with a Q&A session. Investors can register for the event and access live webcasts via the provided links. Cingulate focuses on its proprietary Precision Timed Release™ (PTR™) drug delivery technology for developing next-generation products, initially targeting ADHD.
Cingulate Inc. (NASDAQ: CING) has announced that its Chairman and CEO, Shane J. Schaffer, and scientific advisor, Dr. Ann Childress, will participate in a live event on June 3, 2022, at 8:45 a.m. CST, hosted by Benzinga. The discussion will focus on unmet needs in Attention Deficit/Hyperactivity Disorder (ADHD) and the expansion of Cingulate's Precision Timed Release™ (PTR™) platform into anxiety treatments. This event can be accessed via Benzinga’s YouTube channel and Cingulate's website.
Cingulate Inc. (NASDAQ: CING) announced the completion of enrollment in a clinical study for CTx-2103, a novel buspirone formulation aimed at treating anxiety disorders. This study, initiated in May 2022 with 12 participants, is set to yield results in July 2022. CTx-2103 employs Cingulate's proprietary Precision Timed Release™ (PTR™) technology, enabling once-daily dosing. The formulation could address issues of nonadherence prevalent with current treatments, offering potential for improved patient outcomes in a significant $5.5B U.S. anxiety market.
Cingulate Inc. (NASDAQ: CING), a clinical-stage biopharmaceutical company, will present an overview at the H.C. Wainwright Global Investment Conference on May 25, 2022, from 3:00-3:30 p.m. ET in Miami, FL. The presentation will feature insights from CEO Shane J. Schaffer and CMO Matthew Brams, M.D. Interested investors can access the live webcast and later view a replay on Cingulate’s investor website for 90 days. The company focuses on its proprietary Precision Timed Release™ (PTR™) technology, primarily targeting ADHD treatment while exploring other therapeutic areas like anxiety disorders.
FAQ
What is the current stock price of Cingulate Warrants (CINGW)?
What is the core focus of Cingulate Inc?
What therapeutic areas does Cingulate Inc target?
Who recently joined the Cingulate C-Suite?
What is the unique approach of Cingulate's CTx-1301?
What recent regulatory milestone did Cingulate achieve?
How has Cingulate managed its financials in recent years?
What is the significance of Cingulate's PTR technology?
What is the current focus of Cingulate's research and development efforts?
How does Cingulate plan to expand its product pipeline?
What is the key takeaway from Cingulate's recent financial results?
